Ronald Barrett Net Worth

The estimated Net Worth of Ronald W Barrett is at least $246 Thousand dollars as of 4 December 2017. Ronald Barrett owns over 14,156 units of Concert Pharmaceuticals Inc stock worth over $118,486 and over the last 9 years he sold CNCE stock worth over $0. In addition, he makes $127,827 as Independent Director at Concert Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ronald Barrett CNCE stock SEC Form 4 insiders trading

Ronald has made over 3 trades of the Concert Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 14,156 units of CNCE stock worth $51,669 on 4 December 2017.

The largest trade he's ever made was exercising 17,699 units of Concert Pharmaceuticals Inc stock on 9 November 2015 worth over $20,000. On average, Ronald trades about 4,955 units every 76 days since 2015. As of 4 December 2017 he still owns at least 14,156 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Ronald Barrett stock trades at the bottom of the page.

Ronald Barrett biography

Dr. Ronald W. Barrett Ph.D. serves as Independent Director of the Company. Dr. Barrett has served as a member of our Board since December 2007. Dr. Barrett has served at the Chief Executive Officer and Chairman of the board of directors of Medikine, Inc., a biopharmaceutical company, since June 2017, and served as its Executive Chair from December 2016 to June 2017. Dr. Barrett was a founder of XenoPort, Inc., a biopharmaceutical company, and served as its Chief Executive Officer from 2001 to October 2015, its Chief Scientific Officer from 1999 to 2001 and as a member of its board of directors from 1999 to October 2015. Prior to XenoPort, Dr. Barrett held various positions at Affymax Research Institute, a drug discovery company now owned by GlaxoSmithKline plc, and Abbott Laboratories, a healthcare company. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in Pharmacology from Rutgers University. Barrett’s industry and board experience, including his experience as the chief executive officer of a publicly traded biopharmaceutical company, make him a key contributor to our Board.

What is the salary of Ronald Barrett?

As the Independent Director of Concert Pharmaceuticals Inc, the total compensation of Ronald Barrett at Concert Pharmaceuticals Inc is $127,827. There are 9 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.

What's Ronald Barrett's mailing address?

Ronald's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.

Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V..., and Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.

What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.

Complete history of Ronald Barrett stock trades at Concert Pharmaceuticals Inc

Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Roger Tung,
  President, Chief Executive Officer, Co-Founder, Director
• Nancy Stuart,
  Chief Operating Officer
• Marc Becker,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• James Cassella,
  Chief Development Officer
• Dr. Roger D. Tung,
  Co-Founder, CEO, Pres & Exec. Director
• Dr. James V. Cassella,
  Chief Devel. Officer
• Jesper Hoiland,
  Independent Director
• Richard Aldrich,
  Independent Chairman of the Board, Co-Founder
• Thomas Auchincloss,
  Independent Director
• Ronald Barrett,
  Independent Director
• Peter Hutt,
  Independent Director
• Christine van Heek,
  Independent Director
• Wilfred Jaeger,
  Independent Director
• Richard H. Aldrich M.B.A., Mba,
  Co-Founder & Chairman
• Justine Koenigsberg,
  Senior Vice President, Corporate Communications and Investor Relations
• Jeffrey Munsie,
  Chief Legal Officer, Secretary
• Christine Boisclair,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Nabil Uddin Pharm.D.,
  VP of Corp. Devel.
• Jeffrey A. Munsie,
  Chief Legal Officer & Corp. Sec.
• Marc A. Becker,
  CFO & Principal Accounting Officer
• Nancy Stuart,
  Chief Operating Officer
• Wendall Wierenga,
  Director
• Wilfred Ethree Arch Managem...,
  
• Pauline Mc Gowan,
  VP, Finance
• D. Ryan Daws,
  Chief Financial Officer
• Robert Silverman,
  Senior VP, General Counsel
• Meghan Fitzgerald,
  Director
• Lynette Herscha,
  General Counsel
• Heek Christi Van,
  Director
• Ryan Lynch,
  PAO
• Partners L P/Ilbiotechnolog...,
  
• Leaf Ventures I, L.P.New Le...,
  
• Helmut Schuhsler,
  Director
• John Gordon Freund,
  Director
• Associates Gp Llcqvt Fund V...,
  
• Capital Management Llcbrook...,
  
• Ventures Fund 2004 L P Flag...,
  
• Plc Gsk,
  
• Capital Partners, L.P.Adage...,
  
• Venture Partners Qualified ...,
  
• Life Science Ventures Vi Gm...,
  
• Arch Management Iv, L.L.C.J...,
  
• Arch Management Iii Llcthre...,
  
• Arch Management Iv, L.L.C.J...,
  
• Xii Gp Llc Greylock Xii Lim...,
  
• Arch Management Iii Llcjaeg...,
  
• Jesper Hoeiland,
  Director
• Marc A. Becker,
  Chief Financial Officer